Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 4/20 | 0.36 |
| ▸ | CA2 | P00918 | 4/20 | 0.36 |
| ▸ | MGAM | O43451 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | SI | P14410 | 1/20 | 0.36 |
| ▸ | ACHE | P22303 | 1/20 | 0.36 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.36 |
| ▸ | CA9 | Q16790 | 3/20 | 0.33 |
| ▸ | CA12 | O43570 | 2/20 | 0.31 |
| ▸ | CA4 | P22748 | 2/20 | 0.31 |
| ▸ | CA5A | P35218 | 2/20 | 0.31 |
| ▸ | CA7 | P43166 | 2/20 | 0.31 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.31 |
| ▸ | CA5B | Q9Y2D0 | 2/20 | 0.31 |
| ▸ | CA6 | P23280 | 1/20 | 0.31 |
| ▸ | CA13 | Q8N1Q1 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12389697 | 1.00 | CA1 (0.36) | CA1CA2MGAMGAASI | |
| SCHEMBL18026267 | 1.00 | CA1 (0.36) | CA1CA2MGAMGAASI | |
| SCHEMBL3326331 | 1.00 | CA1 (0.36) | CA1CA2MGAMGAASI | |
| SCHEMBL13298724 | 1.00 | CA1 (0.36) | CA1CA2MGAMGAASI | |
| SCHEMBL13318313 | 1.00 | CA1 (0.36) | CA1CA2MGAMGAASI | |
| SCHEMBL25381577 | 1.00 | CA1 (0.36) | CA1CA2MGAMGAASI | |
| SCHEMBL6931270 | 1.00 | CA1 (0.36) | CA1CA2MGAMGAASI | |
| SCHEMBL3207006 | 1.00 | CA1 (0.36) | CA1CA2MGAMGAASI | |
| SCHEMBL19519647 | 1.00 | CA1 (0.36) | CA1CA2MGAMGAASI | |
| SCHEMBL12792418 | 1.00 | CA1 (0.36) | CA1CA2MGAMGAASI |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 43 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230279170-A1 | CHIRAL-SUBSTITUTED POLY-N-VINYLPYRROLIDINONES AND COMPLEXES WITH BIMETALLIC NANOCLUSTERS AND USES THEREOF | KANSAS STATE UNIVERSITY RESEARCH FOUNDATION | 2023-09-07 | — | — | US | disclosed |
| WO-2022167817-A1 | NOVEL PROCESS | ARTIOS PHARMA LIMITED (GB) | 2022-08-11 | — | — | WO | disclosed |
| US-20210292293-A1 | NOVEL COMPOUND BASED ON VALEROLACTONE AND MEDICINE | KUSAMA, Kuniko (JP) | 2021-09-23 | — | — | US | disclosed |
| US-20210139440-A1 | FATTY ACID DERIVATIVES AND THEIR USE | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVIC (US) | 2021-05-13 | — | — | US | disclosed |
| EP-1807440-B1 | NOVOBIOCIN ANALOGUES AS ANTICANCER AGENTS | UNIV KANSAS (US) | 2020-02-19 | — | — | EP | disclosed |
| EP-2960243-B1 | BIOTIN ALTERANT, STREPTAVIDIN MUTANT, AND USES THEREOF | SAVID THERAPEUTICS INC (JP) | 2019-03-27 | — | — | EP | disclosed |
| WO-2019010414-A1 | FATTY ACID DERIVATIVES AND THEIR USE | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH & HUMAN SERVICES (US) | 2019-01-10 | — | — | WO | disclosed |
| US-9670255-B2 | Modified biotin, mutant streptavidin, and use thereof | SAVID THERAPEUTICS INC. (JP) | 2017-06-06 | — | — | US | disclosed |
| US-9670255-B2 | Modified biotin, mutant streptavidin, and use thereof | SAVID THERAPEUTICS INC. (JP) | 2017-06-06 | — | — | US | disclosed |
| US-20160137704-A1 | MODIFIED BIOTIN, MUTANT STREPTAVIDIN, AND USE THEREOF | SAVID THERAPEUTICS INC. (JP) | 2016-05-19 | — | — | US | disclosed |
| US-7608594-B2 | Novobiocin analogues as anticancer agents | UNIVERSITY OF KANSAS (US) | 2009-10-27 | — | — | US | disclosed |
| US-7608594-B2 | Novobiocin analogues as anticancer agents | UNIVERSITY OF KANSAS (US) | 2009-10-27 | — | — | US | disclosed |
| US-7601852-B2 | Macrocyclic kinase inhibitors | KOSAN BIOSCIENCES INCORPORATED (US) | 2009-10-13 | — | — | US | disclosed |
| US-20090187014-A1 | Novobiocin Analogues | UNIVERSITY OF KANSAS | 2009-07-23 | — | — | US | disclosed |
| US-20090187014-A1 | Novobiocin Analogues | UNIVERSITY OF KANSAS | 2009-07-23 | — | — | US | disclosed |
| US-20090163709-A1 | Novobiocin Analogues Having Modified Sugar Moieties | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2009-06-25 | — | — | US | disclosed |
| US-20090163709-A1 | Novobiocin Analogues Having Modified Sugar Moieties | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2009-06-25 | — | — | US | disclosed |
| US-20070270452-A1 | Novobiocin analogues as neuroprotective agents and in the treatment of autoimmune disorders | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2007-11-22 | — | — | US | disclosed |
| US-20070270452-A1 | Novobiocin analogues as neuroprotective agents and in the treatment of autoimmune disorders | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2007-11-22 | — | — | US | disclosed |
| US-20070265333-A1 | Macrocyclic kinase inhibitors | KOSAN BIOSCIENCES INCORPORATED | 2007-11-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210139440-A1 | FATTY ACID DERIVATIVES AND THEIR USE | FFAR3, FFAR1, FFAR2 | CA1 3255/4885CA2 2799/4885MGAM 4538/4885 |
| US-20070265333-A1 | Macrocyclic kinase inhibitors | MAP3K19, MAP3K20, MAP3K1 | CA1 4777/4885CA2 3825/4885MGAM 3008/4885 |
| US-20090163709-A1 | Novobiocin Analogues Having Modified Sugar Moieties | HSP90AB1, HSP90B1, HSP90AB2P | CA1 2611/4885CA2 4571/4885MGAM 480/4885 |
| US-20210292293-A1 | NOVEL COMPOUND BASED ON VALEROLACTONE AND MEDICINE | CYP17A1, HSD17B7, CYP51A1 | CA1 3992/4885CA2 3346/4885MGAM 962/4885 |
| US-20070270452-A1 | Novobiocin analogues as neuroprotective agents and in the treatment of autoimmune disorders | SSB, IAPP, NLN | CA1 3105/4885CA2 4828/4885MGAM 2299/4885 |
| US-20160137704-A1 | MODIFIED BIOTIN, MUTANT STREPTAVIDIN, AND USE THEREOF | BTD, HLCS, BSG | CA1 4702/4885CA2 4347/4885MGAM 1433/4885 |
| US-20090187014-A1 | Novobiocin Analogues | SSB, SSBP1, BTD | CA1 4147/4885CA2 4855/4885MGAM 1720/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.